SCHEMBL2806034

SCHEMBL2806034

O=C(O)c1cc2[nH]ccc2c(Cl)c1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 3/20 0.44
TPX2 Q9ULW0 3/20 0.44
F7 P08709 1/20 0.41
F3 P13726 1/20 0.41
PRKAB2 O43741 6/20 0.39
PRKAG1 P54619 6/20 0.39
PRKAA2 P54646 6/20 0.39
PRKAA1 Q13131 6/20 0.39
PRKAG3 Q9UGI9 6/20 0.39
PRKAG2 Q9UGJ0 6/20 0.39
PRKAB1 Q9Y478 6/20 0.39
XDH P47989 1/20 0.39
P2RX7 Q99572 3/20 0.38
FTO Q9C0B1 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.37
ENPP2 Q13822 1/20 0.37
HSD17B10 Q99714 1/20 0.37
PTPRC P08575 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5374802 0.76 P2RX7 (0.51) F7F3P2RX7
SCHEMBL28625449 0.75 KDM4E (0.44) AURKATPX2F7F3PRKAB2
SCHEMBL15797442 0.73 P2RX7 (0.51) AURKATPX2F7F3PRKAB2
SCHEMBL31342218 0.73 KDM4E (0.45) AURKATPX2F7F3XDH
SCHEMBL13947815 0.71 AURKA (0.48) AURKATPX2F7F3PRKAB2
SCHEMBL15822895 0.71 P2RX7 (0.54) AURKATPX2F7F3PRKAB2
SCHEMBL15797418 0.70 P2RX7 (0.52) AURKATPX2F7F3PRKAB2
SCHEMBL29047547 0.70 AURKA (0.40) AURKATPX2PRKAB2PRKAG1PRKAA2
SCHEMBL2806054 0.69 AURKA (0.56) AURKATPX2F7F3PRKAB2
SCHEMBL30446838 0.69 AURKA (0.56) AURKATPX2F7F3PRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
CN-101679324-B Morpholine derivatives MITSUBISHI TANABE PHARMA CORP 2012-10-03 CN disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
CN-101679324-A Morpholine derivatives MITSUBISHI TANABE PHARMA CORP 2010-03-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 AURKA 1249/4885TPX2 4513/4885F7 788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.